Clinical Trial Update: Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety [Phase 2]

View source ↗

Summary

Phase 2 trial comparing GSK's DTaP-IPV candidate vaccine with separately administered DTaP and IPV vaccines to assess immune response and safety; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• DTaP-IPV Candidate Vaccine (diphtheria and tetanus toxoids and acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria, Acellular Pertussis | Phase 2 | Status: COMPLETED